FindTrial
Sign In

LBL-007

DRUG9 trials

Sponsors

Beigene Ltd., Beigene Ltd., Beigene Ltd., BeOne Medicines, Nanjing Leads Biolabs Co.,Ltd, BeiGene

Conditions

Advanced MalignanciesAdvanced MelanomaEsophageal CancerEsophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma by AJCC V8 StageHead and Neck CancerHead and Neck Squamous Cell CancerHead and Neck Squamous Cell Carcinoma

Phase 1

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
CompletedNCT04640545
Nanjing Leads Biolabs Co.,LtdAdvanced Melanoma
Start: 2020-05-12End: 2024-08-19Updated: 2025-09-18
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
CompletedCTIS2022-500694-14-00
Beigene Ltd., Beigene Ltd.Head and Neck Squamous Cell Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Start: 2023-06-02End: 2025-02-06Target: 48Updated: 2025-01-31
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Active, not recruitingNCT05609370
BeiGeneUnresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Start: 2023-01-29End: 2026-12-31Updated: 2025-10-02

Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Active, not recruitingNCT05635708
BeiGeneMetastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer
Start: 2023-03-07End: 2026-10-01Target: 400Updated: 2026-03-18
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Active, not recruitingNCT05909904
BeiGeneHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Start: 2023-07-21End: 2026-05-28Target: 160Updated: 2025-10-07
MASTER PROTOCOL: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.
Active, not recruitingCTIS2022-502738-18-00
Beigene Ltd.Metastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer
Start: 2023-09-15Target: 22Updated: 2025-11-18
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Active, not recruitingNCT06010303
BeiGeneEsophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
Start: 2023-11-08End: 2026-05-23Updated: 2025-11-17
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Active, not recruitingCTIS2023-503418-63-00
Beigene Ltd.Head and Neck Squamous Cell Carcinoma
Start: 2023-11-23Target: 28Updated: 2025-07-25

Phase 3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Active, not recruitingNCT04164199
BeOne MedicinesAdvanced Malignancies
Start: 2019-12-19End: 2026-07-01Updated: 2026-03-27

Related Papers

A phase 2 study of LBL-007 (anti-LAG-3) plus tislelizumab (anti-PD-1) and chemotherapy as first-line treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma.
Journal of Clinical Oncology2026-01-10
Abstract CT276: Liberty-201: Maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC)
Cancer Research2024-04-05
Abstract CT277: BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)
Cancer Research2024-04-05
Abstract CT274: BGB-A317-LBL-007-202: A phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC)
Cancer Research2024-04-05
Abstract 4041: Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and < for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and < for clinical potential in solid tumors such as HNSCC
Cancer Research2024-03-22
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
2023-07-2010 citations
Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma.
Journal of Clinical Oncology2023-06-013 citations
Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase Ⅰ, open-label, multicenter, dose escalation/expansion study.
Journal of Clinical Oncology2022-06-013 citations
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
Clinical Cancer Research2021-10-2944 citations